Development and in vitro evaluation of a microbicide gel formulation for a novel non-nucleoside reverse transcriptase inhibitor belonging to the N-dihydro-alkyloxy-benzyl-oxopyrimidines (N-DABOs) family

Cristina Tintori, Annalaura Brai, Maria Chiara Dasso Lang, Davide Deodato, Antonia Michela Greco, Bruno Mattia Bizzarri, Lorena Cascone, Alexandru Casian, Claudio Zamperini, Elena Dreassi, Emmanuele Crespan, Giovanni Maga, Guido Vanham, Elisa Rita Ceresola, Filippo Canducci, Kevin K Ariën, Maurizio Botta

Research output: Contribution to journalA1: Web of Science-article

Abstract

Preventing HIV transmission by the use of a vaginal microbicide is a topic of considerable interest in the fight against AIDS. Both a potent anti-HIV agent and an efficient formulation are required to develop a successful microbicide. In this regard, molecules able to inhibit the HIV replication before the integration of the viral DNA into the genetic material of the host cells, such as entry inhibitors or reverse transcriptase inhibitors (RTIs), are ideal candidates for prevention purpose. Among RTIs, S- and N-dihydro-alkyloxy-benzyl-oxopyrimidines (S-DABOs/N-DABOs) are interesting compounds active at nanomolar concentration against wild type of RT and with a very interesting activity against RT mutations. Herein, novel N-DABOs were synthesized and tested as anti-HIV agents. Furthermore, their mode of binding was studied by molecular modeling. At the same time, a vaginal microbicide gel formulation was developed and tested for one of the most promising candidate.

Original languageEnglish
JournalJ Med Chem
Volume59
Issue number6
Pages (from-to)2747-2759
ISSN0022-2623
DOIs
Publication statusPublished - 2016

Fingerprint

Dive into the research topics of 'Development and in vitro evaluation of a microbicide gel formulation for a novel non-nucleoside reverse transcriptase inhibitor belonging to the N-dihydro-alkyloxy-benzyl-oxopyrimidines (N-DABOs) family'. Together they form a unique fingerprint.

Cite this